SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff and repeated tests of recent lows have traders focused on its heavy debt, financing costs and ability to fund AI infrastructure growth. Bears warn of dilution or financial distress, while bulls point to AI demand and contracted backlog and treat the weakness as a buying opportunity; Goldmans upgrade and ARKs purchases have not ended the debate.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a semiconductor selloff, with traders focused on CEO Hock Tans warning that some AI investing resembles gambling and his comments about capital constraints. The remarks and worries about AI spending and financing have fueled bearish sentiment, while other traders see the pullback as a buying opportunity based on Broadcoms AI-chip growth; many also complain that the stock has lagged semiconductor peers.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is rebounding alongside semiconductor stocks after a steep, extended selloff, drawing dip buyers who see oversold conditions and continued AI-chip demand as support for a recovery. Others warn the bounce may be temporary, citing concerns about AI investment returns and debt, market uncertainty, and upcoming chip-sector earnings.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a prolonged post-IPO selloff, with traders citing lockup expirations and insider-share supply, a TD Cowen price-target cut, and concerns about OpenAI customer concentration, scaling, and Nvidia competition. Bears see continued selling pressure, while bulls argue the decline is overdone and point to Cerebras AI-chip technology and backlog.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is drawing attention over concerns that its debt-funded AI data-center buildout and heavy capital spending could strain cash flow, amplified by widening credit-risk indicators and broader jitters around AI infrastructure financing. Traders are split between fears that spending and customer concentration pose serious risks and the view that Oracles cloud demand and backlog can eventually justify the investment, with some buying the selloff.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs volatile price action is being debated against concerns about token unlocks and dilution, which traders blame for persistent selling. Bulls point to Starknets quantum-resistant technology, Bitcoin integration, privacy features and possible shift to an independent Layer 1, while skeptics question whether those developments can overcome supply pressure.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile AI and semiconductor rebound, as traders debate whether credit strains at AI infrastructure firms such as CoreWeave and uncertain returns on data-center spending could undermine chip demand. Dip buyers see continued AI demand and upcoming hyperscaler earnings and GTC commentary as reasons for confidence, while skeptics warn that the rally may fade.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

A sharp, volatile pullback in Celestica shares is drawing attention, with traders pointing to weakness across AI and data-center infrastructure stocks and continuing concern about dilution from the companys earlier equity offering. Some see the decline as an overreaction given the companys AI-related growth prospects and expect earnings to provide a catalyst, while others remain wary of the downtrend.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Scott Kirbys comments supporting a near-total inheritance tax have drawn sharp criticism, with some traders calling for a boycott of United. The discussion also focuses on the quarterly earnings report and recent share weakness, with traders divided between bearish concerns and potential upside if results and guidance reassure investors.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a steep selloff across neocloud and AI-infrastructure stocks, as traders weigh Gartners warning that massive AI investments may not generate adequate returns and question funding risks; concerns about Horizon 2 handover delays add to the debate. Sentiment is split between traders calling the shares oversold and betting on an AI-demand recovery, and those expecting further downside over execution, financing, and market risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's after-market session. The company's market cap stands at $12.9 million.
Jupiter Neurosciences (NASDAQ:JUNS) stockread more...

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers

Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's regular session. The market value of their outstanding shares is at $20.9 million.
Jupiter Neurosciences (NASDAQ:JUNS)read more...

Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?

Shares of Jupiter Neurosciences are surging Friday morning after partner PharmAla Biotech announced a series of corporate updates.read more...

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers

Werewolf Therapeutics (NASDAQ:HOWL) shares moved upwards by 74.6% to $0.75 during Friday's pre-market session. The company's market cap stands at $20.9 million.
Jupiter Neurosciences (NASDAQ:JUNS)read more...

AI, Biotech and Billion-Dollar Deals Ignite Market Momentum as Breakout Companies Make Big Moves

A fresh round of corporate announcements is highlighting several of Wall Street's strongest investment themes. $JUNS, $KBLB, $KIDZ, $HIHO, $VIVK, $UTZ

Jupiter Neurosciences Lands Potential $100 Million Psychedelic Drug Deal as PharmAla Licenses ALA-002

Momentum continues to build across the emerging psychedelic medicine sector as PharmAla Biotech (OTCQB:MDXXF) announced a definitive licensing agreement granting Jupiter Neurosciences (NASDAQ:JUNS) exclusive rights to develop, manufacture, and commercialize ALA-002 in the United States. The agreement, valued at up to approximately US$100 million in potential consideration, reflects the growing interest in next-generation neuropsychiatric therapies and strategic partnerships designed to advance promising clinical assets while managing development risk.

Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement

The psychedelics market continues to expand rapidly as researchers gain a deeper understanding of its potential therapeutic benefits. Today, a leader in the sector announced a partnership with another micro-cap biotech company to further advance its development efforts in the space. Investors responded positively to the news, sending shares of both companies sharply higher following the announcement.PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) announced that it has signed a term sheet with Jupiter Neurosciences, Inc. (NASDAQ: JUNS) to grant the company exclusive perpetual U.S. ...

Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal

Jupiter Neurosciences shares are rising Wednesday after it announced the acquisition of US licensing rights to ALA-002 from Pharmala Biotech.read more...

JUNS Stock Sees Best Single-Day Gains In Almost A Year On $100M MDMA Drug Licensing Deal  – Retail Expects Shares To Hit $1

Equity

Jupiter Neurosciences signed a term sheet to acquire exclusive U.S. licensing rights to an MDMA-based drug candidate developed by PharmAla Biotech.

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The firm offers JOTROL, an enhanced orally administered resveratrol formulation, designed to deliver therapeutically relevant, safe levels of resveratrol. The company was founded by Christer Rosén, Alexander Rosén, Claes Wahlestedt, Marshall Hayward, and Shaun P. Brothers in January 2016 and is headquartered in Jupiter, FL.

Jupiter Neurosciences Inc

Bearish Sentiment

<ul class="summary-bullets"><li>The agreement carries a potential value of up to $100 million, but Jupiter will make an upfront payment of $3.3 million.</li><li>ALA-002 is a patented MDMA formulation recognized by the U.S. Food and Drug Administration as a novel chemical entity.</li><li>JUNS stock is set to test a key technical milestone for the first time in nearly seven months.</li></ul>Shares of Jupiter Neurosciences, Inc. (JUNS) surged more than 50% in early trade on Wednesday, clocking its biggest single-day gains in nearly a year, after it signed a term sheet to acquire exclusive U.S. licensing rights to an MDMA-based drug candidate developed by PharmAla Biotech.<a href="https://stocktwits.com/symbol/JUNS">JUNS stock</a> is also set to test its 100-day moving average (100-DMA) for the first time since October 2025.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.tradingview.com/chart/teA7VKVN/?symbol=NASDAQ%3AJUNS"><img src="https://news.stocktwits-cdn.com/JUNS_jpg_ca4361f22f.webp" alt="JUNS.jpg"></a>Source: TradingView<h2 class="st-heading-2">JUNS To Pay $3.3M Upfront</h2>As part of the $100 million term sheet, Jupiter will pay $3.33 million upfront, including $1.5 million in cash and $1.83 million in company stock. The deal also includes future milestone payments and royalties tied to the development and commercialization of the therapy.ALA-002 is a patented MDMA formulation recognized by the U.S. Food and Drug Administration (FDA) as a novel chemical entity.&nbsp;The therapy is designed to improve cardiovascular safety and reduce abuse risks while maintaining the therapeutic effects linked to MDMA-assisted treatment.“ALA-002 represents the type of innovative, next-generation asset we believe can play a pivotal role in future neuropsychiatric therapies,” said Alison Silva, President and Chief Business Officer of Jupiter Neurosciences.<h2 class="st-heading-2">Psychedelic Market Sees Regulatory Traction</h2>The announcement comes after President Donald Trump signed an executive order in April aimed at accelerating access to psychedelic treatments for serious mental illnesses such as PTSD. The order directs the regulatory bodies like the FDA and Drug Enforcement Administration (DEA) to expand pathways for investigational psychedelic therapies and increase federal support for related research programs.Jupiter said the deal positions the company to benefit from the fast-growing psychedelic therapeutics market, which is expected to become a multi-billion-dollar industry in the United States.<h2 class="st-heading-2">JUNS Bulls Eye $1</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user saw a strong buying opportunity at current levels, adding that there is a “green light going forward.”<stembedurl>https://stocktwits.com/Yiota/message/653906655</stembedurl>Another user said the stock could climb to $1.<stembedurl>https://stocktwits.com/KevMomentum/message/653901396</stembedurl>JUNS shares have tanked around 60% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-roiv-stock-is-rising-today/cZXDUfNReVv">ROIV Stock Nears Record High: Moderna Settlement Drives Q4 Profit, But Pipeline Catalysts Keep Retail Interested</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A Tiny Psychedelic Stock Just Exploded Over 50% – Retail Traders Think $1 Is Next

Jupiter Neurosciences Inc.

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$2.75
Prev Close	$2.91
Open	$2.77
Dividend Yield	0.00%
50-Day Moving Average	$3.61
Beta	0.47
Avg. Volume	54,821.98
PE Ratio	-0.14

52-Week High	$135.75
52-Week Low	$2.25
Market Capitalization	$3.83M
EPS (Annual)	-$18.72
Price to Book	-4.99
Revenue Per Employee	$4,359.20

Feed

News

Sentiment

Fundamentals

Info

JUNS Fundamentals